Alniditan
chemical compound
Alniditan (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name R-91274) is a selective serotonin 5-HT1B and 5-HT1D receptor agonist with migraine-preventive effects which was never marketed. It was under development for treatment of migraine via subcutaneous injection in the 1990s and reached phase 3 clinical trials for this indication prior to the discontinuation of its development.
Pharmacology
Pharmacodynamics
Alniditan acts as a selective serotonin 5-HT1B and 5-HT1D receptor full agonist. To a much lesser extent, it is also a full agonist of the serotonin 5-HT1A receptor and an agonist of the serotonin 5-HT2B receptor. Conversely, alniditan is essentially inactive at the serotonin 5-HT1E, 5-HT1F, and 5-HT2A receptors. The broad receptor interactions of alniditan have been studied and reported.
Pharmacokinetics
The elimination half-life of alniditan is relatively long at 8 to 13 hours.
Chemistry
Synthesis
The sizeable number of serotonergic drugs for treating migraines all incorporate the indole nucleus found in serotonin itself. It is thus of interest that a compound based on a benzopyran manifests much the same activity.
Alkylation of phenol with 2-bromobutyrolactone (2) leads to the ether (3).
Begin with the source’s own compact description: “Alniditan” is chemical compound. The dossier treats that line as a proposition to test through Alniditan, chemical and compound, not as a finished interpretation.
Why this record matters
The phrase “chemical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Nov 27, 2025. The linked authority identifier is Q4734060. None of the 0 selected statements returned an explicit reference.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Alniditan”, its source revision and the description used here.
- Expand the search: follow Alniditan primary sources, Alniditan archive and Alniditan research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Alniditan”?
- Has classification or technical consensus changed since the cited source?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “Alniditan” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.